121 related articles for article (PubMed ID: 9338619)
21. Activity of 2-chlorodeoxyadenosine (Cladribine) in 2-hour intravenous infusion in 94 previously treated patients with low grade non-Hodgkin's lymphoma.
Róbak T; Gora-Tybor J; Krykowski E; Walewski JA; Borawska A; Pluźańska A; Potemski P; Hellmann A; Zaucha JM; Konopka L; Ceglarek B; Durźyński T; Sikorska A; Michalak K; Urasiński J; Opalińska J; Dmoszyńska A; Adamczyk-Cioch MB; Kuratowska Z; Dwilewicz-Trojaczek J; Boguradzki P; Deren M; Maj S; Grieb P
Leuk Lymphoma; 1997 Jun; 26(1-2):99-105. PubMed ID: 9250793
[TBL] [Abstract][Full Text] [Related]
22. Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma.
Robak T; Smolewski P; Cebula B; Szmigielska-Kaplon A; Chojnowski K; Blonski JZ
Cancer; 2006 Oct; 107(7):1542-50. PubMed ID: 16948126
[TBL] [Abstract][Full Text] [Related]
23. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications.
Lauria F; Bocchia M; Marotta G; Raspadori D; Zinzani PL; Rondelli D
Haematologica; 1999 Jan; 84(1):22-5. PubMed ID: 10091389
[TBL] [Abstract][Full Text] [Related]
24. 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland.
Robak T; Błasińska-Morawiec M; Błoński J; Hellmann A; Hałaburda K; Konopka L; Kotlarek-Haus S; Potoczek S; Hansz J; Dmoszyńska A; Urasiński I; Zdziarska B; Dwilewicz-Trojaczek J; Hołowiecki J; Skotnicki AB
Eur J Haematol; 1999 Jan; 62(1):49-56. PubMed ID: 9918312
[TBL] [Abstract][Full Text] [Related]
25. Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma.
Rummel MJ; Chow KU; Karakas T; Jäger E; Mezger J; von Grünhagen U; Schalk KP; Burkhard O; Hansmann ML; Ritzel H; Bergmann L; Hoelzer D; Mitrou PS
Eur J Cancer; 2002 Sep; 38(13):1739-46. PubMed ID: 12175690
[TBL] [Abstract][Full Text] [Related]
26. Infectious complications after 2-chlorodeoxyadenosine therapy.
Van Den Neste E; Delannoy A; Vandercam B; Bosly A; Ferrant A; Mineur P; Montfort L; Martiat P; Straetmans N; Filleul B; Michaux JL
Eur J Haematol; 1996 Apr; 56(4):235-40. PubMed ID: 8641392
[TBL] [Abstract][Full Text] [Related]
27. 2-chlorodeoxyadenosine (2-CdA) in 2-hour versus 24-hour intravenous infusion in the treatment of patients with hairy cell leukemia.
Robak T; Błasińska-Morawiec M; Krykowski E; Hansz J; Komarnicki M; Kazimierczak M; Konopka L; Maj S; Hellmann A; Zaucha JM; Urasiński L; Zdziarska B; Kotlarek-Haus S; Usnarska-Zubkiewicz L; Kuratowska Z; Dwilewicz-Trojaczek J; Hołowiecki J; Krawczyk-Kulis M; Grieb P
Leuk Lymphoma; 1996 Jun; 22(1-2):107-11. PubMed ID: 8724536
[TBL] [Abstract][Full Text] [Related]
28. Profound toxicity of deoxyadenosine and 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo.
Carrera CJ; Yamanaka H; Piro LD; Lotz M; Carson DA
Adv Exp Med Biol; 1989; 253B():219-25. PubMed ID: 2575348
[TBL] [Abstract][Full Text] [Related]
29. 2-Chlorodeoxyadenosine therapy in advanced chronic lymphocytic leukaemia.
Delannoy A; Ferrant A; Martiat P; Montfort L; Doyen C; Sokal G; Michaux JL
Nouv Rev Fr Hematol (1978); 1994 Aug; 36(4):311-5. PubMed ID: 7971251
[TBL] [Abstract][Full Text] [Related]
30. High incidence of complications after 2-chloro-2'-deoxyadenosine combined with cyclophosphamide in patients with advanced lymphoproliferative malignancies.
Van Den Neste E; Michaux L; Layios N; Costantini S; Francart J; Lambert C; Sonet A; André M; Robert A; Ferrant A
Ann Hematol; 2004 Jun; 83(6):356-63. PubMed ID: 15024607
[TBL] [Abstract][Full Text] [Related]
31. 2-Chlorodeoxyadenosine in the treatment of relapsed/refractory chronic lymphoproliferative disorders.
Rondelli D; Lauria F; Zinzani PL; Raspadori D; Ventura MA; Galieni P; Birtolo S; Forconi F; Algeri R; Tura S
Eur J Haematol; 1997 Jan; 58(1):46-50. PubMed ID: 9020373
[TBL] [Abstract][Full Text] [Related]
32. Association of myelodysplastic changes with purine analogues.
Orchard JA; Bolam S; Oscier DG
Br J Haematol; 1998 Mar; 100(4):677-9. PubMed ID: 9531333
[TBL] [Abstract][Full Text] [Related]
33. Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukaemia treated with cladribine.
Robak T; Blonski JZ; Gora-Tybor J; Kasznicki M; Konopka L; Ceglarek B; Komarnicki M; Lewandowski K; Hellmann A; Lewandowski K; Moskwa A; Dmoszyńska A; Sokołowska B; Dwilewicz-Trojaczek A; Tomaszewska A; Sułek K; Całbecka M
Eur J Cancer; 2004 Feb; 40(3):383-9. PubMed ID: 14746857
[TBL] [Abstract][Full Text] [Related]
34. Factors affecting bryostatin 1-enhanced 2-CdA cytotoxicity in resistant B-cell chronic lymphocytic leukemia.
Beck FW; Eilender DS; Dandashi MH; Siddiq F; Snell DC; Godmere MA; Al-Katib AM; Mohammad RM
Int J Mol Med; 2004 Jul; 14(1):113-9. PubMed ID: 15202025
[TBL] [Abstract][Full Text] [Related]
35. Pentostatin and 2-chlorodeoxyadenosine for hairy-cell leukemia.
Med Lett Drugs Ther; 1992 Sep; 34(879):89-90. PubMed ID: 1355592
[No Abstract] [Full Text] [Related]
36. Hypereosinophilia during 2-chlorodeoxyadenosine treatment for hairy cell leukaemia.
Rutella S; Sica S; Rumi C; Martucci R; Etuk B; De Stefano V; Testa U; Leone G; Peschle C
Br J Haematol; 1996 Feb; 92(2):426-8. PubMed ID: 8603011
[TBL] [Abstract][Full Text] [Related]
37. 2-Chlorodeoxyadenosine therapy in Waldenstrom's macroglobulinaemia.
Delannoy A; Ferrant A; Martiat P; Bosly A; Zenebergh A; Michaux JL
Nouv Rev Fr Hematol (1978); 1994 Aug; 36(4):317-20. PubMed ID: 7971252
[TBL] [Abstract][Full Text] [Related]
38. 2-Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma.
Saven A; Carrera CJ; Carson DA; Beutler E; Piro LD
Blood; 1992 Aug; 80(3):587-92. PubMed ID: 1353380
[TBL] [Abstract][Full Text] [Related]
39. Cladribine in the treatment of chronic lymphocytic leukemia.
Robak T
Leuk Lymphoma; 2001 Feb; 40(5-6):551-64. PubMed ID: 11426528
[TBL] [Abstract][Full Text] [Related]
40. Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine.
Carson DA; Wasson DB; Esparza LM; Carrera CJ; Kipps TJ; Cottam HB
Proc Natl Acad Sci U S A; 1992 Apr; 89(7):2970-4. PubMed ID: 1348362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
